Ludwig Enterprises, Inc. · OTC:LUDG
Ludwig Enterprises — Investor Presentation (August 2024)
21 slides from Ludwig Enterprises's investor presentation, August 2024
Slide 1: The Future of Early Home Diagnostics
THE FUTURE OF EARLY HOME DIAGNOSTICS We aim to disrupt the cancer diagnos cs market with a patent pending mRNA mail-order cheek swab. It is the easiest, most accurate, cancer screening test on the market. ti
Slide 2: Forward Looking Statements
Forward Looking Statements This presenta on contains forward-looking statements that involve risks and uncertain es. These statements include projec ons of nancial performance, management's plans, and future economic condi ons. Forward-looking statements are based on current assump ons and may di er
Slide 3: The Problem
The Problem 3 Cancer caught early can help Current cancer screenings are prevent 70% of early deaths. inconvenient or invasive. 40.5% of people will be diagnosed with Most cancer screenings are so inconvenient, cancer at some point during their life mes. that they are o en put o and avoided by ~ Na
Slide 4: Early Detection Is Often a Cure
EARLY DETECTION IS OFTEN A CURE Cancer causes 600,000 American and nearly 10 million global deaths annually. According to the WHO, 70% of these deaths are preventable.* Reference: Quan ta ve es mates of preventable and treatable deaths from 36 cancers worldwide: a popula on-based study November 2023
Slide 5: The most convenient, painless multi-cancer early detection screening
We’ve invented the most convenient, painless multi-cancer early detection screening on the market …leveraging nanoscale detection technology + AI
Slide 6: Mail-order cheek swab detects early signals for multiple cancers
With a simple mail-order cheek swab we can detect early signals for: ✓ Breast cancer ✓ Bladder cancer ✓ Colon cancer …and more.
Slide 7: Our Technology Disrupts Early Disease Detection
OUR TECHNOLOGY DISRUPTS EARLY DISEASE DETECTION Our patent-pending multi-cancer screening technology offers a painless, convenient, and accurate alternative to other cancer screenings. Nanoscale + AI Analy cs = Breakthrough Diagnos cs ti ti
Slide 8: Breakthrough Diagnostics: Over 3,000 Patients Tested
Over 3,000 Patients Tested Our Mul Center IRB approved 40 Clinic Trial cancer screening analyzed by AI to discover dozens of signals and indicate best treatment Breakthrough Diagnostics World Renowned Research We can detect a broad range of cancers Hundreds of peer-reviewed ar cles in and in ammator
Slide 9: Product Development Excellence
9 Cheek Swab Technology Top Rated Results Lab Cheek swabs are by far the easiest most Our lab has the coveted and convenient, least expensive solu on in highest possible ra ngs with cancer detec on - and we’re the only both CLIA and CAP cer ca ons. ones with the tech & rights to use it. Powerful IP
Slide 10: Patent Protection
PATENT PROTECTION ✓ ✓ Cheek swab mRNA cancer detec on ✓ ✓ Lab chip sequencing to detect nanoscale mRNA ✓ ✓ 48 mRNA biomarkers for cancer detec on ✓ September 20, 2022-2023 Provisionals mRNA gene panel, cheek samples, diagnosis of in ammatory diseases and cancer and evalua ng response to treatment of
Slide 11: Competitive Analysis
Compe ve Analysis 11 Other breast cancer screenings are painful, dif cult and inaccurate TEST DIFFICULTY COST ACCCURACY Simple, painless, 2 minute cheek swab you can do any me anywhere then drop $149 - LUDWIG in the mail whenever - even if the completed test has been le out for weeks. 97% Sensi vity
Slide 12: Industry Landscape
12 Industry Landscape Cancer screenings & diagnostics are primed for disruption We Change the Game. We are the rst to be able to analyze cheek swabs for Less Cologuard Urine Cytology auria tears Our cheek swab nanogram quan es of cancer signals Invasive Inconvenient & Unreliable The leading mul -can
Slide 13: Ludwig Milestones
Ludwig Milestones How we disrupt the $200+ billion diagnostics market Patents pending on nanoscale signals our AI can use to detect many types of cancer and other progressive diseases Invented AI driven process gets nanogram quantities of cancer signals effectively Over 3,000 people analyzed for dia
Slide 14: Market Size
14 Market Size Our markets grow as we advance $200B+ $100B $31B YEAR I YEAR 2 YEAR 3 5 Cancer Screens Cancer Diagnostic Market Global Diagnostic Markets $4.7 Billion Breast Cancer Provide a full mul -cancer screening Provide a universal disease screening $15.48 Billion Colon Cancer test, along with
Slide 15: Go to Market Strategy
15 Go to Market Strategy Our Roadmap to Launch in October 2024 2022: Patent Pending IP protec on for: ✓ Cheek swab mRNA cancer detec on ✓ Lab chip sequencing to detect nanoscale mRNA ✓ 48 mRNA biomarkers for cancer detec on and other in ammatory diseases ti fl ti ti
Slide 16: Go to Market Strategy
16 Go to Market Strategy 01 02 03 Posi on & Messaging: Branding & Packaging: Technical Marke ng & Ads: The Easiest & Most Branding & marke ng 30 years experience in data- Accurate Breast Cancer exper se who’s worked driven and viral online Screening on the Market with top brands marke ng & adver sin
Slide 17: Team
TEAM 17 CTO CEO COO CFO Dr. Kyle H. Ambert Marvin S. Hausman, M.D. Antonio Reyes Scott Silverman PhD in Biomedical Informa cs. Dr. Immunologist and Board-Cer ed Execu ve with experience as a Founder, Sco , a nancial execu ve with 25+ years Ambert is currently the Director of Data Urological Surgeon.
Slide 18: $950K Raise
18 $950K Raise ✓ Uplist prepara on ✓ Product Launch prepara on $7 Million Uplist ✓ Go-to-Market Strategy When we Uplist our stock ✓ Product Design exchange we expect to ✓ Brand design bring in $5-7 million in ✓ Sales funnel development addi onal funding so we ✓ Ful llment prepara on can scale quickl
Slide 19: 3rd Party Insurance Reimbursement and Diagnostics Dominance
19 3rd Party Insurance Reimbursement Our customers no longer have to pay for our tests. When this happened for Cologuard their revenue per test jumped from $249 to $1500. 2025 2027 2026 DIAGNOSTICS DOMINANCE We become a market leader providing Peer Reviewed Studies cheek-swab based AI-driven diagnos
Slide 20: Investment Highlights
20 Investment Highlights 1. Innovative Technology: Ludwig Enterprises has developed a proprietary, patent-pending multi-cancer early detection screening technology that offers a painless, convenient, and highly accurate alternative to traditional cancer screenings. 2. Market Disruption Potential: Th
Slide 21: The Future of Early Home Diagnostics
THE FUTURE OF EARLY HOME DIAGNOSTICS We aim to disrupt the cancer diagnos cs market with a patent pending mRNA mail-order cheek swab. It is the easiest, most accurate, cancer screening test on the market. ti
Ludwig Enterprises — Investor Presentation (August 2024) on 6ix